{"entity":{"type":"insider","cik":"0001759241","url":"/insider/0001759241","json_url":"/insider/0001759241.json","name":"Atlas Venture Opportunity Fund I, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":133,"n_filings":25,"first":"2019-06-25","last":"2024-03-13","span_basis":"filed_date"},"name_variants":[{"name":"Atlas Venture Opportunity Fund I, L.P.","source":"filing","n_filings":25,"first_seen":"2019-06-25","last_seen":"2024-03-13"}],"transactions":[{"id":2130872,"accession":"0001415889-24-007894","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001415889-24-007894","line_url":"/filing/0001415889-24-007894#line-12","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates X, LLC; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":108404.0,"shares_display":"108,404","price_per_share":42.19,"price_display":"42.19","price_state":"stated","total_value":4573564.76,"total_display":"4,573,564.76","shares_owned_after":4682761.0,"shares_owned_after_display":"4,682,761","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-13","filed_date":"2024-03-13","scope":"insider"},{"id":2130867,"accession":"0001415889-24-007894","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001415889-24-007894","line_url":"/filing/0001415889-24-007894#line-11","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates X, LLC; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22779.0,"shares_display":"22,779","price_per_share":42.19,"price_display":"42.19","price_state":"stated","total_value":961046.01,"total_display":"961,046.01","shares_owned_after":830216.0,"shares_owned_after_display":"830,216","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-13","filed_date":"2024-03-13","scope":"insider"},{"id":2130864,"accession":"0001415889-24-007894","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001415889-24-007894","line_url":"/filing/0001415889-24-007894#line-10","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates X, LLC; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6686.0,"shares_display":"6,686","price_per_share":42.84,"price_display":"42.84","price_state":"stated","total_value":286428.24,"total_display":"286,428.24","shares_owned_after":4676075.0,"shares_owned_after_display":"4,676,075","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-13","filed_date":"2024-03-13","scope":"insider"},{"id":2130859,"accession":"0001415889-24-007894","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001415889-24-007894","line_url":"/filing/0001415889-24-007894#line-9","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates X, LLC; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1386.0,"shares_display":"1,386","price_per_share":42.84,"price_display":"42.84","price_state":"stated","total_value":59376.24,"total_display":"59,376.24","shares_owned_after":828830.0,"shares_owned_after_display":"828,830","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-13","filed_date":"2024-03-13","scope":"insider"},{"id":2130856,"accession":"0001415889-24-007894","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001415889-24-007894","line_url":"/filing/0001415889-24-007894#line-8","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates X, LLC; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":126066.0,"shares_display":"126,066","price_per_share":41.94,"price_display":"41.94","price_state":"stated","total_value":5287208.04,"total_display":"5,287,208.04","shares_owned_after":4799746.0,"shares_owned_after_display":"4,799,746","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-12","filed_date":"2024-03-13","scope":"insider"},{"id":2130852,"accession":"0001415889-24-007894","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001415889-24-007894","line_url":"/filing/0001415889-24-007894#line-7","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates X, LLC; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26452.0,"shares_display":"26,452","price_per_share":41.94,"price_display":"41.94","price_state":"stated","total_value":1109396.88,"total_display":"1,109,396.88","shares_owned_after":854814.0,"shares_owned_after_display":"854,814","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-12","filed_date":"2024-03-13","scope":"insider"},{"id":2130849,"accession":"0001415889-24-007894","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-24-007894","line_url":"/filing/0001415889-24-007894#line-6","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates X, LLC; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8581.0,"shares_display":"8,581","price_per_share":42.52,"price_display":"42.52","price_state":"stated","total_value":364864.12,"total_display":"364,864.12","shares_owned_after":4791165.0,"shares_owned_after_display":"4,791,165","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-12","filed_date":"2024-03-13","scope":"insider"},{"id":2130846,"accession":"0001415889-24-007894","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001415889-24-007894","line_url":"/filing/0001415889-24-007894#line-5","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates X, LLC; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1819.0,"shares_display":"1,819","price_per_share":42.52,"price_display":"42.52","price_state":"stated","total_value":77343.88,"total_display":"77,343.88","shares_owned_after":852995.0,"shares_owned_after_display":"852,995","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-12","filed_date":"2024-03-13","scope":"insider"},{"id":2130842,"accession":"0001415889-24-007894","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-007894","line_url":"/filing/0001415889-24-007894#line-4","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates X, LLC; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37180.0,"shares_display":"37,180","price_per_share":42.77,"price_display":"42.77","price_state":"stated","total_value":1590188.6,"total_display":"1,590,188.60","shares_owned_after":4930934.0,"shares_owned_after_display":"4,930,934","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-11","filed_date":"2024-03-13","scope":"insider"},{"id":2130836,"accession":"0001415889-24-007894","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-007894","line_url":"/filing/0001415889-24-007894#line-3","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates X, LLC; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7837.0,"shares_display":"7,837","price_per_share":42.77,"price_display":"42.77","price_state":"stated","total_value":335188.49,"total_display":"335,188.49","shares_owned_after":882311.0,"shares_owned_after_display":"882,311","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-11","filed_date":"2024-03-13","scope":"insider"},{"id":2130832,"accession":"0001415889-24-007894","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-007894","line_url":"/filing/0001415889-24-007894#line-2","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates X, LLC; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5122.0,"shares_display":"5,122","price_per_share":43.42,"price_display":"43.42","price_state":"stated","total_value":222397.24,"total_display":"222,397.24","shares_owned_after":4925812.0,"shares_owned_after_display":"4,925,812","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-11","filed_date":"2024-03-13","scope":"insider"},{"id":2130827,"accession":"0001415889-24-007894","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-007894","line_url":"/filing/0001415889-24-007894#line-1","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates X, LLC; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1045.0,"shares_display":"1,045","price_per_share":43.42,"price_display":"43.42","price_state":"stated","total_value":45373.9,"total_display":"45,373.90","shares_owned_after":881266.0,"shares_owned_after_display":"881,266","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-11","filed_date":"2024-03-13","scope":"insider"},{"id":3052919,"accession":"0001415889-24-006764","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-006764","line_url":"/filing/0001415889-24-006764#line-2","is_derivative":false,"issuer_cik":"0001759241","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001759241","owner_cik":null,"owner_name":"Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund II, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29435.0,"shares_display":"29,435","price_per_share":30.05,"price_display":"30.05","price_state":"stated","total_value":884521.75,"total_display":"884,521.75","shares_owned_after":1458691.0,"shares_owned_after_display":"1,458,691","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-01","filed_date":"2024-03-05","scope":"insider"},{"id":3052914,"accession":"0001415889-24-006764","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-006764","line_url":"/filing/0001415889-24-006764#line-1","is_derivative":false,"issuer_cik":"0001759241","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001759241","owner_cik":null,"owner_name":"Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund II, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17099.0,"shares_display":"17,099","price_per_share":30.05,"price_display":"30.05","price_state":"stated","total_value":513824.95,"total_display":"513,824.95","shares_owned_after":847388.0,"shares_owned_after_display":"847,388","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-01","filed_date":"2024-03-05","scope":"insider"},{"id":2928271,"accession":"0001415889-24-005777","txn_seq":18,"anchor":"line-18","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-18","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":152244.0,"shares_display":"152,244","price_per_share":24.83,"price_display":"24.83","price_state":"stated","total_value":3780218.52,"total_display":"3,780,218.52","shares_owned_after":5700521.0,"shares_owned_after_display":"5,700,521","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-28","filed_date":"2024-02-28","scope":"insider"},{"id":2928268,"accession":"0001415889-24-005777","txn_seq":17,"anchor":"line-17","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-17","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22567.0,"shares_display":"22,567","price_per_share":24.83,"price_display":"24.83","price_state":"stated","total_value":560338.61,"total_display":"560,338.61","shares_owned_after":1488486.0,"shares_owned_after_display":"1,488,486","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-28","filed_date":"2024-02-28","scope":"insider"},{"id":2928263,"accession":"0001415889-24-005777","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-16","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13109.0,"shares_display":"13,109","price_per_share":24.83,"price_display":"24.83","price_state":"stated","total_value":325496.47,"total_display":"325,496.47","shares_owned_after":864697.0,"shares_owned_after_display":"864,697","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-28","filed_date":"2024-02-28","scope":"insider"},{"id":2928259,"accession":"0001415889-24-005777","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-15","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2430.0,"shares_display":"2,430","price_per_share":25.25,"price_display":"25.25","price_state":"stated","total_value":61357.5,"total_display":"61,357.50","shares_owned_after":5698091.0,"shares_owned_after_display":"5,698,091","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-28","filed_date":"2024-02-28","scope":"insider"},{"id":2928255,"accession":"0001415889-24-005777","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-14","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":360.0,"shares_display":"360","price_per_share":25.25,"price_display":"25.25","price_state":"stated","total_value":9090.0,"total_display":"9,090.00","shares_owned_after":1488126.0,"shares_owned_after_display":"1,488,126","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-28","filed_date":"2024-02-28","scope":"insider"},{"id":2928251,"accession":"0001415889-24-005777","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-13","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":210.0,"shares_display":"210","price_per_share":25.25,"price_display":"25.25","price_state":"stated","total_value":5302.5,"total_display":"5,302.50","shares_owned_after":864487.0,"shares_owned_after_display":"864,487","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-28","filed_date":"2024-02-28","scope":"insider"},{"id":2928249,"accession":"0001415889-24-005777","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-12","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":272923.0,"shares_display":"272,923","price_per_share":24.38,"price_display":"24.38","price_state":"stated","total_value":6653862.74,"total_display":"6,653,862.74","shares_owned_after":5878544.0,"shares_owned_after_display":"5,878,544","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-27","filed_date":"2024-02-28","scope":"insider"},{"id":2928246,"accession":"0001415889-24-005777","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-11","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40455.0,"shares_display":"40,455","price_per_share":24.38,"price_display":"24.38","price_state":"stated","total_value":986292.9,"total_display":"986,292.90","shares_owned_after":1514874.0,"shares_owned_after_display":"1,514,874","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-27","filed_date":"2024-02-28","scope":"insider"},{"id":2928244,"accession":"0001415889-24-005777","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-10","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25779.0,"shares_display":"25,779","price_per_share":24.68,"price_display":"24.68","price_state":"stated","total_value":636225.72,"total_display":"636,225.72","shares_owned_after":5852765.0,"shares_owned_after_display":"5,852,765","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-27","filed_date":"2024-02-28","scope":"insider"},{"id":2928238,"accession":"0001415889-24-005777","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-9","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23505.0,"shares_display":"23,505","price_per_share":24.38,"price_display":"24.38","price_state":"stated","total_value":573051.9,"total_display":"573,051.90","shares_owned_after":880022.0,"shares_owned_after_display":"880,022","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-27","filed_date":"2024-02-28","scope":"insider"},{"id":2928232,"accession":"0001415889-24-005777","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-8","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3821.0,"shares_display":"3,821","price_per_share":24.68,"price_display":"24.68","price_state":"stated","total_value":94302.28,"total_display":"94,302.28","shares_owned_after":1511053.0,"shares_owned_after_display":"1,511,053","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-27","filed_date":"2024-02-28","scope":"insider"},{"id":2928228,"accession":"0001415889-24-005777","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-7","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2216.0,"shares_display":"2,216","price_per_share":24.68,"price_display":"24.68","price_state":"stated","total_value":54690.88,"total_display":"54,690.88","shares_owned_after":877806.0,"shares_owned_after_display":"877,806","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-27","filed_date":"2024-02-28","scope":"insider"},{"id":2928222,"accession":"0001415889-24-005777","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-6","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":136312.0,"shares_display":"136,312","price_per_share":23.59,"price_display":"23.59","price_state":"stated","total_value":3215600.08,"total_display":"3,215,600.08","shares_owned_after":6216250.0,"shares_owned_after_display":"6,216,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-26","filed_date":"2024-02-28","scope":"insider"},{"id":2928217,"accession":"0001415889-24-005777","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-5","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":64783.0,"shares_display":"64,783","price_per_share":23.98,"price_display":"23.98","price_state":"stated","total_value":1553496.34,"total_display":"1,553,496.34","shares_owned_after":6151467.0,"shares_owned_after_display":"6,151,467","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-26","filed_date":"2024-02-28","scope":"insider"},{"id":2928212,"accession":"0001415889-24-005777","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-4","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20205.0,"shares_display":"20,205","price_per_share":23.59,"price_display":"23.59","price_state":"stated","total_value":476635.95,"total_display":"476,635.95","shares_owned_after":1564932.0,"shares_owned_after_display":"1,564,932","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-26","filed_date":"2024-02-28","scope":"insider"},{"id":2928206,"accession":"0001415889-24-005777","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-3","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11736.0,"shares_display":"11,736","price_per_share":23.59,"price_display":"23.59","price_state":"stated","total_value":276852.24,"total_display":"276,852.24","shares_owned_after":909107.0,"shares_owned_after_display":"909,107","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-26","filed_date":"2024-02-28","scope":"insider"},{"id":2928202,"accession":"0001415889-24-005777","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-2","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9603.0,"shares_display":"9,603","price_per_share":23.98,"price_display":"23.98","price_state":"stated","total_value":230279.94,"total_display":"230,279.94","shares_owned_after":1555329.0,"shares_owned_after_display":"1,555,329","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-26","filed_date":"2024-02-28","scope":"insider"},{"id":2928196,"accession":"0001415889-24-005777","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777#line-1","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5580.0,"shares_display":"5,580","price_per_share":23.98,"price_display":"23.98","price_state":"stated","total_value":133808.4,"total_display":"133,808.40","shares_owned_after":903527.0,"shares_owned_after_display":"903,527","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-26","filed_date":"2024-02-28","scope":"insider"},{"id":2659297,"accession":"0001415889-24-005124","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-24-005124","line_url":"/filing/0001415889-24-005124#line-6","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":159542.0,"shares_display":"159,542","price_per_share":22.7,"price_display":"22.70","price_state":"stated","total_value":3621603.4,"total_display":"3,621,603.40","shares_owned_after":6352562.0,"shares_owned_after_display":"6,352,562","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-23","filed_date":"2024-02-23","scope":"insider"},{"id":2659289,"accession":"0001415889-24-005124","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001415889-24-005124","line_url":"/filing/0001415889-24-005124#line-5","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23648.0,"shares_display":"23,648","price_per_share":22.7,"price_display":"22.70","price_state":"stated","total_value":536809.6,"total_display":"536,809.60","shares_owned_after":1585137.0,"shares_owned_after_display":"1,585,137","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-23","filed_date":"2024-02-23","scope":"insider"},{"id":2659284,"accession":"0001415889-24-005124","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-005124","line_url":"/filing/0001415889-24-005124#line-4","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13738.0,"shares_display":"13,738","price_per_share":22.7,"price_display":"22.70","price_state":"stated","total_value":311852.6,"total_display":"311,852.60","shares_owned_after":920843.0,"shares_owned_after_display":"920,843","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-23","filed_date":"2024-02-23","scope":"insider"},{"id":2659279,"accession":"0001415889-24-005124","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-005124","line_url":"/filing/0001415889-24-005124#line-3","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":119360.0,"shares_display":"119,360","price_per_share":22.66,"price_display":"22.66","price_state":"stated","total_value":2704697.6,"total_display":"2,704,697.60","shares_owned_after":6512104.0,"shares_owned_after_display":"6,512,104","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-22","filed_date":"2024-02-23","scope":"insider"},{"id":2659275,"accession":"0001415889-24-005124","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-005124","line_url":"/filing/0001415889-24-005124#line-2","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":149337.0,"shares_display":"149,337","price_per_share":22.44,"price_display":"22.44","price_state":"stated","total_value":3351122.28,"total_display":"3,351,122.28","shares_owned_after":6666628.0,"shares_owned_after_display":"6,666,628","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-21","filed_date":"2024-02-23","scope":"insider"},{"id":2659271,"accession":"0001415889-24-005124","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-005124","line_url":"/filing/0001415889-24-005124#line-1","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35164.0,"shares_display":"35,164","price_per_share":23.14,"price_display":"23.14","price_state":"stated","total_value":813694.96,"total_display":"813,694.96","shares_owned_after":6631464.0,"shares_owned_after_display":"6,631,464","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-21","filed_date":"2024-02-23","scope":"insider"},{"id":2698180,"accession":"0001209191-24-003031","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-24-003031","line_url":"/filing/0001209191-24-003031#line-2","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Xilio Therapeutics, Inc.","issuer_ticker":"XLO","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Associates XI, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":733.0,"shares_display":"733","price_per_share":0.64,"price_display":"0.64","price_state":"stated","total_value":469.12,"total_display":"469.12","shares_owned_after":2019563.0,"shares_owned_after_display":"2,019,563","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-08","filed_date":"2024-02-09","scope":"insider"},{"id":2698172,"accession":"0001209191-24-003031","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-24-003031","line_url":"/filing/0001209191-24-003031#line-1","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Xilio Therapeutics, Inc.","issuer_ticker":"XLO","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Associates XI, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":267.0,"shares_display":"267","price_per_share":0.64,"price_display":"0.64","price_state":"stated","total_value":170.88,"total_display":"170.88","shares_owned_after":734546.0,"shares_owned_after_display":"734,546","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-08","filed_date":"2024-02-09","scope":"insider"},{"id":2178391,"accession":"0001209191-24-002231","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-24-002231","line_url":"/filing/0001209191-24-002231#line-3","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Disc Medicine, Inc.","issuer_ticker":"IRON","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Associates X, LLC; Atlas Venture Associates Opportunity I, L.P.; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Fund X, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":82500.0,"shares_display":"82,500","price_per_share":67.65,"price_display":"67.65","price_state":"stated","total_value":5581125.0,"total_display":"5,581,125.00","shares_owned_after":703660.0,"shares_owned_after_display":"703,660","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-23","filed_date":"2024-01-25","scope":"insider"},{"id":2178388,"accession":"0001209191-24-002231","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-24-002231","line_url":"/filing/0001209191-24-002231#line-2","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Disc Medicine, Inc.","issuer_ticker":"IRON","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Associates X, LLC; Atlas Venture Associates Opportunity I, L.P.; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Fund X, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":47500.0,"shares_display":"47,500","price_per_share":67.65,"price_display":"67.65","price_state":"stated","total_value":3213375.0,"total_display":"3,213,375.00","shares_owned_after":1402186.0,"shares_owned_after_display":"1,402,186","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-23","filed_date":"2024-01-25","scope":"insider"},{"id":2178384,"accession":"0001209191-24-002231","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-24-002231","line_url":"/filing/0001209191-24-002231#line-1","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Disc Medicine, Inc.","issuer_ticker":"IRON","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Associates X, LLC; Atlas Venture Associates Opportunity I, L.P.; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Fund X, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":67.65,"price_display":"67.65","price_state":"stated","total_value":1353000.0,"total_display":"1,353,000.00","shares_owned_after":198326.0,"shares_owned_after_display":"198,326","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-23","filed_date":"2024-01-25","scope":"insider"},{"id":2981676,"accession":"0001209191-24-001655","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-24-001655","line_url":"/filing/0001209191-24-001655#line-4","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Xilio Therapeutics, Inc.","issuer_ticker":"XLO","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1540.0,"shares_display":"1,540","price_per_share":0.83,"price_display":"0.83","price_state":"stated","total_value":1278.2,"total_display":"1,278.20","shares_owned_after":2020296.0,"shares_owned_after_display":"2,020,296","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-12","filed_date":"2024-01-16","scope":"insider"},{"id":2981668,"accession":"0001209191-24-001655","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-24-001655","line_url":"/filing/0001209191-24-001655#line-3","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Xilio Therapeutics, Inc.","issuer_ticker":"XLO","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":560.0,"shares_display":"560","price_per_share":0.83,"price_display":"0.83","price_state":"stated","total_value":464.8,"total_display":"464.80","shares_owned_after":734813.0,"shares_owned_after_display":"734,813","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-12","filed_date":"2024-01-16","scope":"insider"},{"id":2981664,"accession":"0001209191-24-001655","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-24-001655","line_url":"/filing/0001209191-24-001655#line-2","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Xilio Therapeutics, Inc.","issuer_ticker":"XLO","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1566.0,"shares_display":"1,566","price_per_share":0.87,"price_display":"0.87","price_state":"stated","total_value":1362.42,"total_display":"1,362.42","shares_owned_after":2021836.0,"shares_owned_after_display":"2,021,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-11","filed_date":"2024-01-16","scope":"insider"},{"id":2981659,"accession":"0001209191-24-001655","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-24-001655","line_url":"/filing/0001209191-24-001655#line-1","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Xilio Therapeutics, Inc.","issuer_ticker":"XLO","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":569.0,"shares_display":"569","price_per_share":0.87,"price_display":"0.87","price_state":"stated","total_value":495.03,"total_display":"495.03","shares_owned_after":735373.0,"shares_owned_after_display":"735,373","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-11","filed_date":"2024-01-16","scope":"insider"},{"id":2424022,"accession":"0001209191-24-001540","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-24-001540","line_url":"/filing/0001209191-24-001540#line-2","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Disc Medicine, Inc.","issuer_ticker":"IRON","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Fund X, L.P.; Atlas Venture Associates Opportunity I, L.P.; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Associates X, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":64.0,"price_display":"64.00","price_state":"stated","total_value":1920000.0,"total_display":"1,920,000.00","shares_owned_after":1449686.0,"shares_owned_after_display":"1,449,686","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-10","filed_date":"2024-01-12","scope":"insider"},{"id":2424014,"accession":"0001209191-24-001540","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-24-001540","line_url":"/filing/0001209191-24-001540#line-1","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Disc Medicine, Inc.","issuer_ticker":"IRON","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Fund X, L.P.; Atlas Venture Associates Opportunity I, L.P.; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Associates X, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":64.0,"price_display":"64.00","price_state":"stated","total_value":1280000.0,"total_display":"1,280,000.00","shares_owned_after":786160.0,"shares_owned_after_display":"786,160","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-10","filed_date":"2024-01-12","scope":"insider"},{"id":8754150,"accession":"0001209191-23-058707","txn_seq":22,"anchor":"line-22","filing_url":"/filing/0001209191-23-058707","line_url":"/filing/0001209191-23-058707#line-22","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Disc Medicine, Inc.","issuer_ticker":"IRON","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Associates Opportunity I, LLC; Atlas Venture Fund X, L.P.; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates X, LLC; Atlas Venture Associates Opportunity I, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30645.0,"shares_display":"30,645","price_per_share":58.27,"price_display":"58.27","price_state":"stated","total_value":1785684.15,"total_display":"1,785,684.15","shares_owned_after":1479866.0,"shares_owned_after_display":"1,479,866","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-14","filed_date":"2023-12-14","scope":"insider"}],"next_cursor":"2023-12-14|8754150","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001815442","name":"Kymera Therapeutics, Inc.","url":"/issuer/0001815442","role":"Ten percent owner","n_filings":5,"first_seen":"2022-11-01","last_seen":"2024-03-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001818794","name":"Dyne Therapeutics, Inc.","url":"/issuer/0001818794","role":"Ten percent owner","n_filings":4,"first_seen":"2022-12-14","last_seen":"2024-03-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001840233","name":"Xilio Therapeutics, Inc.","url":"/issuer/0001840233","role":"Ten percent owner","n_filings":3,"first_seen":"2021-10-26","last_seen":"2024-02-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001816736","name":"Disc Medicine, Inc.","url":"/issuer/0001816736","role":"Ten percent owner","n_filings":4,"first_seen":"2023-08-16","last_seen":"2024-01-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001923840","name":"Third Harmonic Bio, Inc.","url":"/issuer/0001923840","role":"Ten percent owner","n_filings":1,"first_seen":"2022-09-19","last_seen":"2022-09-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001845337","name":"Day One Biopharmaceuticals, Inc.","url":"/issuer/0001845337","role":"Ten percent owner","n_filings":2,"first_seen":"2021-06-02","last_seen":"2022-06-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001827087","name":"Vigil Neuroscience, Inc.","url":"/issuer/0001827087","role":"Ten percent owner","n_filings":1,"first_seen":"2022-01-11","last_seen":"2022-01-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001835579","name":"Ikena Oncology, Inc.","url":"/issuer/0001835579","role":"Ten percent owner","n_filings":1,"first_seen":"2021-12-14","last_seen":"2021-12-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001733294","name":"Generation Bio Co.","url":"/issuer/0001733294","role":"Ten percent owner","n_filings":3,"first_seen":"2021-06-28","last_seen":"2021-09-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001744659","name":"Akero Therapeutics, Inc.","url":"/issuer/0001744659","role":"Ten percent owner","n_filings":1,"first_seen":"2019-06-25","last_seen":"2019-06-25"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001759241","retrieved_at":"2026-08-21T23:29:11+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}